Abstract |
Uracil mustard was used for the treatment of thrombocytosis in 14 patients, eight who had polycythemia vera and six who had essential thrombocytosis. Intermittent treatment with 1 to 2 mg/day for 14 days was used for most patients, and continuous treatment was used for three patients. The nadir of the platelet count occurred during a mean period of five to seven weeks, and the mean duration between courses was seven months. The drug selectively depressed the platelet count, with a minimal effect on leukocytes and erythrocytes. Uracil mustard is an effective drug for the control of thrombocytosis.
|
Authors | H K Shamasunder, S A Gregory, W H Knospe |
Journal | JAMA
(JAMA)
Vol. 244
Issue 13
Pg. 1454-5
(Sep 26 1980)
ISSN: 0098-7484 [Print] United States |
PMID | 7420634
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Administration, Oral
(methods)
- Humans
- Platelet Count
- Polycythemia Vera
(blood, drug therapy)
- Thrombocytosis
(drug therapy)
- Uracil Mustard
(therapeutic use)
|